- Home
- NEGG vs ORIC Comparison
NEGG vs ORIC Comparison
Compare NEGG & ORIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NEGG | ORIC |
|---|---|---|
| Founded | 2001 | 2014 |
| Country | United States | United States |
| Employees | 762 | N/A |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 883.1M | 837.3M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | NEGG | ORIC |
|---|---|---|
| Price | $22.32 | $8.37 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 13 |
| Target Price | N/A | ★ $19.73 |
| AVG Volume (30 Days) | 74.3K | ★ 1.2M |
| Earning Date | 04-28-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 19.67 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.70 | $4.65 |
| 52 Week High | $137.84 | $14.93 |
Technical Indicators
Market Signals| Indicator | NEGG | ORIC |
|---|---|---|
| Relative Strength Index (RSI) | 24.38 | 33.01 |
| Support Level | N/A | $7.90 |
| Resistance Level | $47.10 | $13.89 |
| Average True Range (ATR) | 2.75 | 0.50 |
| MACD | -1.21 | -0.10 |
| Stochastic Oscillator | 2.76 | 4.02 |
Price Performance
Historical ComparisonAbout NEGG Newegg Commerce Inc.
Newegg Commerce Inc is an e-commerce company offering direct sales and an online marketplace platform for IT computer components, consumer electronics, entertainment, smart home, and gaming products and provides certain third-party logistics services globally. Geographically, it operates in United States, Canada, and Rest of World.
About ORIC Oric Pharmaceuticals Inc.
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.